BrightGene Bio Medical Technology C

BrightGene Bio-Medical's holding subsidiary, Atmen (Suzhou) Pharmaceutical, has received marketing authorization from the National Medical Products Administration for tiotropium bromide inhalation spray, becoming the first domestic company to win approval for this generic drug. The product is a Category 4 chemical drug, delivering 2.5 micrograms of tiotropium bromide per spray, with 60 sprays per bottle. The manufacturer is BrightGene Pharmaceutical (Suzhou), and the approval number is valid until July 27, 2031. The company stated that this approval further enriches its respiratory product pipeline and helps enhance market competitiveness. However, due to uncertainties such as industry policies and the market environment, the impact of this approval on the company's operating performance remains uncertain.

As of 2:45 p.m. on July 22, 2026, constituents of the SSE STAR Board Biomedical Index were mixed. BrightGene led gains with 12.20%, Medicilon rose 5.98%, Bloomage Biotechnology gained 5.40%, while Hotgen Biotech led declines. The Sci-Tech Innovation Board Healthcare ETF Huaxia last traded at 1.05 yuan, with intraday turnover of 15.98% and turnover of 61.5624 million yuan. Average daily turnover over the past week was 77.0437 million yuan. In news, as of July 20, 94 of the 504 A-share pharmaceutical and biotech companies had disclosed earnings forecasts, a disclosure rate of 18.65%. Among them, 55 companies reported positive net profit growth for the first half of the year, accounting for 58.51%. The innovative drug industry chain and the CXO sector performed notably well. Tianfeng Securities pointed out that in the first half of 2026, there were 621 global transactions, of which 90 involved Chinese molecules, accounting for 14.5%. The total global transaction value reached 302.893 billion US dollars, of which Chinese molecules accounted for 95.905 billion US dollars, or 31.66%. The influence of Chinese innovative molecules is steadily growing worldwide. The Sci-Tech Innovation Board Healthcare ETF Huaxia closely tracks the SSE STAR Board Biomedical Index, which selects 50 listed companies in the biomedical and related fields with larger market capitalizations from the STAR Board as samples. The top ten weighted stocks account for a combined 51.84%.

The STAR Market Healthcare ETF ChinaAMC, ticker 588130, rose 3.04%, with its latest scale reaching 274 million yuan, a new high in nearly one year. The ETF has seen net inflows for 13 consecutive days, attracting a total of 165 million yuan, with an average daily net inflow of 12.701 million yuan. The SSE STAR Market Biomedical Index surged 2.55%, with constituent stocks BrightGene and Dizal Pharmaceutical both up 20.01%. Orient Securities noted that the innovative drug industry has gained global competitiveness, and the new edition of the National Essential Medicines List includes innovative drugs for the first time, making the industry's development prospects worth looking forward to.